There are several treatments available for<unk> ; they all replace deficient FVII. # Recombinant FVIIa concentrate (rFVIIa) is a recombinant treatment that is highly effective and has no risk of fluid overload or viral disease. It may be the optimal therapy. # Plasma derived<unk> <unk>  concentrate (pdFVII) : This treatment is suitable for surgery but can lead to thrombosis. It is virus attenuated. # Prothrombin complex concentrate (PCC) containing<unk> <unk> : this treatment is suitable for surgery, but has a risk of thrombosis. It is virus attenuated. # Fresh frozen plasma (FFP): This is relatively inexpensive and readily available. While effective this treatment carries a risk of blood-borne viruses and fluid overload.
Factor VII deficiency
Factor XII deficiency
Factor XIII deficiency
Protein C deficiency
Factor X deficiency
Factor I deficiency
COAT platelet defect
Activated protein C resistance